Chinese Guidelines for Diagnosis and Treatment of Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome (2024 Edition)

In 2005, the AIDS Working Group of the Chinese Society of Infectious Diseases, Chinese Medical Association, formulated the "Guideline for Diagnosis and Treatment of AIDS" in China (hereinafter referred to as the "Guideline"). The 2024 edition of the "Guideline" is revised based on the 5th edition in 2021, with reference to the latest research progress at home and abroad. The new edition focuses on updates to antiviral therapy, comprehensive management, opportunistic infections, human immunodeficiency virus (HIV) infection complicated with tumors, prevention and intervention of HIV infection, and newly introduces the section on "immunological non-responder (INR) in AIDS", for the first time proposing the concept of "vulnerable populations with AIDS", and adding recommendations for diagnosis and treatment, as well as evidence and strength of recommendation. The "Guideline" covers epidemiology, etiological characteristics, laboratory testing, pathogenesis, clinical manifestations and staging, diagnostic criteria, common opportunistic infections, antiviral therapy, immune reconstitution inflammatory syndrome, INR, AIDS-related tumors, prevention of mother-to-child vertical transmission of HIV and fertility in single-positive families, pre- and post-exposure prophylaxis and interruption of HIV infection, comprehensive management of HIV infection, etc. The "Guideline" aims to assist clinicians in making rational decisions in the diagnosis, treatment, and management of AIDS. It will also be regularly revised and updated according to research progress at home and abroad.